Olysio^® (simeprevir)

1. Souhrn údajů o přípravku. Olysio^® 150 mg cps. [online]. Dostupné z: www.sukl.cz. Citováno 30. 6. 2016.

2. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-control­led trial. Lancet 2014; 384(9941): 403– 413. doi: 10.1016/ S0140-6736(14)60494-3.

3. Kwo P, Gitlin N, Nahass R et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cir­rhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64(2): 370– 380. doi: 10.1002/ hep.28467.

4. Lawitz E, Matusow G, DeJesus E. Sime­previr plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cir­rhosis: a phase 3 study (OPTIMIST-2). Hepatology 2016; 64(2): 360– 369. doi: 10.1002/ hep.28422.

5. Man­ns M, Marcel­lin P, Poordad F et al.

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-control­led phase 3

trial. Lancet 2014; 384(9941): 414– 426. doi: 10.1016/ S0140-6736(14)60538-9.

6. Forns X, Lawitz E, Zeuzem S et al. Sime­previr with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146(7): 1669– 1679. doi: 10.1053/ j.gastro.2014.02.051.

7. El Raziky M, Gamil M, Ham­mad R et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: results from a Phase IIa, partial­ly randomised, open-label trial conducted in Egypt (OSIRIS). Poster presented at: American As­sociation for the Study of Liver Disease (AASLD). 15 November 2015: San Francisco, USA.

8. Buti M. Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: a Phase III, open-label study. Presented at: EASL International Liver Congress (ILC). 13– 17 April 2016: Barcelona, Spain.

9. Moreno C, Hezode C, Marcel­lin P et al. Ef­ficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62(5): 1047– 1055. doi: 10.1016/ j.jhep.2014.12.031.

10. Wil­lemse SB, Baak LC, Kuiken SD et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cir­rhosis is highly ef­ficacious in real life. J Viral Hepat 2016. In pres­s. doi: 10.1111/ jvh.12567.